Keywords: Dual EGFR/HER2 inhibitors; Resistance; T790M/L858R mutant EGFR; Irreversible inhibitors; ADMET; Absorption/Distribution/Metabolism/Excretion/Toxicity; Cbl; Casitas B-lineage Lymphoma; c-MET; cellular mesenchymal to epithelial transition factor; DM; double